Mediacom world news portal
Juluca, the world’s first ever two-drug regimen to fight HIV has finally been approved by the Food and Drug Association in the United States.
Juluca has been approved as a “complete regiment for the maintenance treatment of HIV-1 infection in adults who are virologically suppressed.” The regimen is advisable for those who do not have any history of treatment failure and “no known substitutions associated with resistance to the individual components of Juluca,” according to the press release from Viiv Healthcare, the global specialist HIV company.
The two-drug regiment comprises of dolutegravir and rilprivirine, a reverse transcriptase inhibitor.
There are some side effects that are expected to happen for those who will take the drug, but it is reportedly fewer and less harmful than the ones available on the market.
The most known side effects were headache and diarrhea. More serious side effects include liver problems, allergic reactions, rash, depression or mood change.